INGN Company Profile and Key Details

INGN has shown mixed momentum, losing 0.0% over the past week and -25.81% over the past quarter, though year-to-date performance is down -7.59%. Short-term trend indicators are bullishly aligned (SMA20 10.12%, SMA50 2.59%, SMA200 -8.8%). The stock’s 14-day RSI is 61.31 (firm momentum), while the ATR of 0.32 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -46.06% below its high and over 20.6% above its low. Average 10-day trading volume of 345.79 thousand shares is slightly above the 3-month average of 285.75 thousand, indicating heightened recent market interest.

Inogen, Inc. generated EPS of -$0.86 over the past year. Five-year average earnings growth is -26.38%. The latest quarter delivered EPS of -$0.20. The next quarter is forecast at -$0.28. Next year's EPS is expected at $33.08. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $14.00 to $12.00. The high target offers 95.8% upside. The low target suggests 67.83% downside. The mean target is $13.00. This offers 81.82% upside. Inogen, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 05, 2025, missed forecasts by -8.88%. The prior quarter beat by -31.82%. Over the last six quarters, Apple has recorded several small beats. These include -55.56% in August 06, 2024.

Inogen, Inc. has 27.04 million shares outstanding. The public float is 23.96 million shares, elevated short interest at 3.33% of float. This equals 892.30 thousand shares. The short ratio is 5.11 days. Institutional investors hold 87.08% of the float. Insiders own 11.97%. Novo Holdings A/S holds 2.08 million shares, Smith Kevin Raymond Merrill has 70.27 thousand shares and Taylor Brenton has 56.86 thousand shares.

Inogen, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$6.81. This means the shares are trading below this model’s fair value.

Inogen, Inc. (NASDAQ:INGN) closed at $6.99 USD, losing -$0.16 (-2.24%) from the previous close of $7.15. The stock is currently mid-range between its 52-week high and low $5.34 and $9.13. With a market capitalization of about $190.35 million, Inogen, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.71). Key stats such as the average daily volume over the past year has been around 295.34 thousand shares, volume is running light vs its 52-week average. Headquartered in Goleta, CA, Inogen, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Kevin R. Smith, the company employs approximately 766 people and listed since February 14, 2014. Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally.

Inogen, Inc. trades at a P/E ratio of -8.25, slightly below the S&P 500 average, with a price-to-sales ratio of 0.54 and a price-to-book ratio of 0.98 suggesting the stock is closer to book value. The P/FCF stands at -8.84, also below market averages.

Our AI price prediction model suggests that Inogen, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.24%, with price expected at $7.31 by May 06, 2026, within a range of $6.06 to $8.59 3-Month Outlook: Projected rise of 42.38%, reaching $10.18 by July 21, 2026, with a range of $9.57 to $10.80. 1-Year Outlook: Projected gain of 58.32%, with price at $11.32 by April 22, 2027, within a range of $3.30 to $13.23.

Inogen, Inc. (NASDAQ:INGN) shares are flat -7.59% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Inogen, Inc. trading at a premium to the broader market with a P/E of -8.25. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $94.59, suggesting 1222.94% upside. Our AI forecast model points to short-term strength (2.24% over two weeks), a medium-term rise (42.38% over three months), and a longer-term gain (58.32% over one year), with expected trading ranges indicating moderate volatility.